FDA 認可するs 発射 for 冷淡な-like winter ウイルス that kills hundreds of babies each year
- The FDA has 認可するd a new 発射 to 扱う／治療する RSV in children and toddlers
- The 医薬 is 推定する／予想するd to be 利用できる by the 近づいている 落ちる RSV season
- READ MORE: FDA 認可するs first-ever ワクチン for RSV ウイルス
The Food and 麻薬 行政 (FDA) has 認可するd a new 麻薬 to 保護する 幼児s and toddlers against respiratory syncytial ウイルス, also known as RSV, and is 推定する／予想するd to be rolled out by 落ちる.?
The 医薬, 製造（する）d by Sanofi and AstraZeneca, will be one of the first 保護s against the illness, which has 殺到するd throughout the 部隊d 明言する／公表するs, filling hospitals and 感染 millions of children every year.??
'RSV can 原因（となる） serious 病気 in 幼児s and some children and results in a large number of 緊急 department and 内科医 office visits each year,' said John Farley, director of the Office of 感染性の 病気s in the FDA’s 中心 for 麻薬 Evaluation and 研究.?
'Today’s 是認 演説（する）／住所s the 広大な／多数の／重要な need for 製品s to help 減ずる the 衝撃 of RSV 病気 on children, families and the health care system.'
Beyfortus, made by Sanofi and AstraZeneca, is a ワクチン 認可するd for 幼児s and toddlers with RSV
認可するd Monday, the 治療, dubbed Beyfortus, is a monoclonal antibody 発射. Monoclonal antibodies are synthetic proteins that 行為／法令／行動する like human antibodies in the 免疫の system. They're often used in 癌 治療 to destroy outer 層s of malignant 独房s.?
The news comes months after the FDA 認可するd two ワクチンs?against the ウイルス for adults older than 60.?
RSV is a respiratory ウイルス that 原因（となる）s 冷淡な-like symptoms in both children and adults. Symptoms, によれば the American 肺 協会, 含む congestion, runny nose, fever, cough, and sore throat. 厳しい 調印するs that 令状 緊急の care are difficulty breathing, not drinking enough, 減少（する）d activity, and blue lips or fingernails.?
Young children and older adults are the most 攻撃を受けやすい groups to the ウイルス.??
The 中心s for 病気 支配（する）／統制する and 予防 (CDC) 見積（る） that RSV accounts for more than two million outpatient visits a year の中で children younger than five years old. Up to 80,000 are 入院させるd 毎年.?
The ウイルス has also been linked to 60,000 入院s and 10,000 deaths in adults 65 years and older.?
The 発射 has been 実験（する）d in more than 3,200 幼児s. One 熟考する／考慮する 設立する that the efficacy over six months against 厳しい RSV that 要求するd 医療の 介入 was 79 パーセント.?
Other 研究 has shown the 麻薬 has 70 to 75 パーセント 有効性.?
Another ワクチン from Pfizer, which would be used during pregnancy to 妨げる the 病気 in 幼児s during their first six months, is 現在／一般に を待つing FDA 是認.
